NCT05883124View on ClinicalTrials.gov

Rivastigmine Bioequivalence Trial With Multiple Applications of Transdermal Patches (9.5 mg/24 h)

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

April 17, 2023

Primary Completion Date

June 19, 2023

Study Completion Date

July 21, 2023

Conditions
Bioequivalence
Interventions
DRUG

Rivastigmine twice-weekly 9,5 mg/24 h

3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period

DRUG

Exelon® 9.5 mg/24 h

11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period

Trial Locations (1)

99084

SocraTec R&D GmbH, Clinical Pharmacology Unit, Erfurt

All Listed Sponsors
lead

SocraTec R&D GmbH

OTHER